TapewireFind a company

person · Reporting owner

Eldridge, George Arthur

Disclosed activity across 1 company

Tapewire entity
160917
SEC CIK
0001622905

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Protara Therapeutics, Inc.PRTO · Entity 6203Sr VP, CFO, Treasr, Asst SecyJanuary 18, 2019January 23, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Protara Therapeutics, Inc.

Report date January 18, 2019 · Filed January 23, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.64 · Expires 2029-01-17Direct145,000 Reported balance After 2019-01-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2019-01-18 · Grant · Acquired 145,000 · Balance 145,000

F1: The options were granted on January 18, 2019 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments.

Filing footnotes · ownership attribution and instrument terms

F1: The options were granted on January 18, 2019 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
January 18, 2019 Filed Jan 23, 2019 21:18 UTC Protara Therapeutics, Inc. PRTO · Entity 6203 GrantStock Option (Right to Buy) · Derivative 145,000 $0.00 Strike: $2.64 $0.00
Disclosure

SEC source: 0001171843-19-000436 · ownership.xml · derivative · entry 1

Eldridge, George Arthur · CIK 0001622905 · Sr VP, CFO, Treasr, Asst Secy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,000

Underlying: Common Stock, $0.001 par value · 145,000 shares

Expires 2029-01-17

F1 · derivative.exercise_date: The options were granted on January 18, 2019 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments.

Read SEC document
December 31, 2018 Filed Jan 3, 2019 13:19 UTC Protara Therapeutics, Inc. PRTO · Entity 6203 GrantCommon Stock 2,448 $1.93 $4,724.64
Disclosure

SEC source: 0001171843-19-000064 · ownership.xml · nonDerivative · entry 1

Eldridge, George Arthur · CIK 0001622905 · Sr VP, CFO, Treasr, Asst Secy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,132

F1 · kind: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan for the plan period of July 1, 2018 through December 31, 2018 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Read SEC document
June 29, 2018 Filed Jul 3, 2018 12:19 UTC Protara Therapeutics, Inc. PRTO · Entity 6203 GrantCommon Stock 10,000 $1.62 $16,150.00
Disclosure

SEC source: 0001171843-18-004989 · ownership.xml · nonDerivative · entry 1

Eldridge, George Arthur · CIK 0001622905 · Sr VP, CFO, Treasr, Asst Secy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,684

F1 · kind: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan for the plan period of January 1, 2018 through June 30, 2018 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Read SEC document
January 17, 2018 Filed Jan 18, 2018 22:16 UTC Protara Therapeutics, Inc. PRTO · Entity 6203 GrantStock Option (Right to Buy) · Derivative 200,000 $0.00 Strike: $2.85 $0.00
Disclosure

SEC source: 0001171843-18-000441 · formfour.xml · derivative · entry 1

Eldridge, George Arthur · CIK 0001622905 · Sr VP, CFO, Treasr, Asst Secy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock, $0.001 par value · 200,000 shares

Expires 2028-01-16

F1 · derivative.exercise_date: The options were granted on January 17, 2018 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments.

Read SEC document
December 29, 2017 Filed Jan 3, 2018 13:16 UTC Protara Therapeutics, Inc. PRTO · Entity 6203 GrantCommon Stock 3,934 $1.30 $5,098.46
Disclosure

SEC source: 0001171843-18-000082 · form4eldridge.xml · nonDerivative · entry 1

Eldridge, George Arthur · CIK 0001622905 · Sr VP, CFO, Treasr, Asst Secy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,684

F1 · kind: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan for the plan period of July 1, 2017 through December 31, 2017 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Read SEC document
November 14, 2017 Filed Nov 14, 2017 22:05 UTC Protara Therapeutics, Inc. PRTO · Entity 6203 PurchaseCommon Stock 295 $1.69 $498.55
Disclosure

SEC source: 0001171843-17-007021 · f4_111417eldridge.xml · nonDerivative · entry 1

Eldridge, George Arthur · CIK 0001622905 · Sr VP, CFO, Treasr, Asst Secy

10b5-1 filing: Not disclosed

Ownership: Indirect · As custodian for child's UTMA account

Disclosed balance after: 1,545

F1 · ownership.nature: These securities were purchased by the reporting person as custodian for three minor children under the Uniform Transfers to Minors Act. The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.

Read SEC document
June 30, 2017 Filed Jul 5, 2017 20:11 UTC Protara Therapeutics, Inc. PRTO · Entity 6203 GrantCommon Stock 10,000 $1.30 $12,960.00
Disclosure

SEC source: 0001171843-17-003952 · formfour.xml · nonDerivative · entry 1

Eldridge, George Arthur · CIK 0001622905 · Sr VP, CFO, Treasr, Asst Secy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,750

F1 · kind: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Read SEC document
January 24, 2017 Filed Jan 26, 2017 13:00 UTC Protara Therapeutics, Inc. PRTO · Entity 6203 GrantStock Option (Right to Buy) · Derivative 53,119 $0.00 Strike: $2.05 $0.00
Disclosure

SEC source: 0001171843-17-000452 · formfour.xml · derivative · entry 1

Eldridge, George Arthur · CIK 0001622905 · Snr VP,CFO,Treasurer,Asst Secy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,119

Underlying: Common Stock, $0.001 par value · 53,119 shares

Expires 2027-01-23

F1 · derivative.exercise_date: The options were granted on January 24, 2017 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.